Ipilimumab is a fully human, monoclonal antibody that blocks the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) signalling, which induces an unrestrained T-cell activation and proliferation and amplifies T-cell-mediated immunity (anti-tumour immune response) [30,31]. Here, CTLA4 is linked to neoplasm.